Regeneron Pharmaceuticals Inc. buy melinda
Start price
09.09.17
/
50%
€409.51
Target price
26.12.17
€505.12
Performance (%)
-16.04%
End price
26.12.17
€343.82
Summary
This prediction ended on 26.12.17 with a price of €343.82. The price of Regeneron Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.04%. melinda has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 7.756% | 7.756% | 22.311% | 119.637% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
According to melinda what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Raymond James Surpass $ 566
Sanofi-Aventis
Sanofi und Regeneron bekannt , dass die FDA die Bezeichnung „Discovery - Capital“ in cemiplimab (REGN2810) bei der Behandlung von kutanen Plattenepithelkarzinomen im fortgeschrittenen Stadium erteilt
STMicroelectronics
STMicroelectronics tritt in den CAC40
(Vom Mitglied beendet)
Stopped prediction by melinda for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€533.60
09.11.21
09.11.21
€600.00
09.11.22
09.11.22
38.91%
10.11.22
10.11.22
Could be worthwhile Investment >10% per year
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€354.55
11.02.20
11.02.20
€500.00
04.11.21
04.11.21
57.95%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€336.00
02.12.18
02.12.18
€356.29
11.01.19
11.01.19
9.01%
11.01.19
11.01.19
Could be worthwhile Investment >10% per year
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€312.09
10.03.18
10.03.18
€351.78
02.08.18
02.08.18
13.53%
02.08.18
02.08.18
Could be worthwhile Investment >10% per year
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€454.00
09.09.17
09.09.17
€560.00
26.12.17
26.12.17
-16.04%
26.12.17
26.12.17
Could be worthwhile Investment >10% per year
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€329.64
15.03.16
15.03.16
€517.75
08.08.16
08.08.16
15.29%
08.08.16
08.08.16
Could be worthwhile Investment >10% per year
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€176.40
01.07.13
01.07.13
€200.00
01.01.14
01.01.14
13.91%
01.01.14
01.01.14
Could be worthwhile Investment >10% per year
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€26.03
07.01.11
07.01.11
€28.00
07.07.11
07.07.11
53.42%
07.07.11
07.07.11
Could be worthwhile Investment >10% per year